Tenofovir disoproxil fumarate (TDF) is increasingly used in patients with chronic hepatitis B (CHB) infection. Although associated with renal toxicity in HIV-infected patients, renal dysfunction has been reported rarely in the monoinfected CHB population. To date, TDF-associated Fanconi syndrome has not been reported. Here, we present two cases of TDF-associated Fanconi syndrome with rapid resolution after its cessation. We then discuss risk factors for TDF nephrotoxicity and its implications for screening for renal disease in those patients with CHB monoinfection on TDF, and the use of TDF in at-risk populations.
References
1.
GallantJ.E., DeJesusE., ArribasJ.R.Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine and efavirenz for HIV. N Engl J Med2006; 354: 251–260.
2.
YuenM.F., LaiC.Treatment of chronic hepatits B: evolution over two decades. J Gastroenterol Hepatol2011; 26Suppl 1: 138–143.
DaudéM., RostaingL., SauneK.Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients. Transplantation2011; 91: 916–920.
8.
HallA.M., HendryB.M., NitschD.Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis2011; 57: 773–780.
FontanaR.J.Side effects of long-term oral antiviral therapy for Hepatits B. Hepatology2009; 49Suppl 1: S185–S195.
11.
GaraN., ZhaoX., CollinsM.T.Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther2012; 35: 1317–1325.
12.
Van RompayK.K.A., Durand-GasselinL., BrignoloL.L.Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother2008; 52: 3144–3160.
13.
PolS., LamperticoP.First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real life’ settings: from clinical trials to clinical practice. J Viral Hepat2012; 19: 377–386.
14.
MaussS., BergerF., FilmannN.Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol2011; 55: 1235–1240.
15.
LamperticoP., SoffrediniR., ViganoM.2 Year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatits B: a multicentre European study in clinical practice. Hepatology2011; 54Suppl 1: 262A.
16.
IzzedineH., HulotJ.S., Launay-VacherV.Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double blind, randomized, placebo controlled studies. Kidney Int2004; 66: 1153–1158.
17.
GuptaS.K., EustaceJ.A., WintonJ.A.Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis2005; 40: 1559.
18.
LiawY.F., LeungN., KaoJ.H.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int2008; 2: 263–283.